Age, years | 50.2 (11.9) | 53.7 (13.3) | 52.6 (11.6) | 53.2 (12.3) | 53.2 (12.4) | 52.4 (12.3) |
Female, No (%) | 57 (81) | 61 (85) | 57 (81) | 50 (69) | 168 (78) | 225 (79) |
RA duration, years | 9.4 (6.6) | 10.4 (7.3) | 10.0 (7.0) | 10.1 (7.9) | 10.2 (7.4) | 10.0 (7.2) |
RF positivity, No (%) | 59 (84) | 61 (85) | 64 (91) | 54 (75.0) | 179 (84) | 238 (84) |
Pretreatment AEs, No (%) | 38 (54) | 47 (65) | 44 (63) | 47 (65) | 138 (65) | 176 (62) |
Prior DMARDs, n† | 3.54 | 4.07 | 3.67 | 3.71 | 3.82 | 3.75 |
Patients undergoing previous joint procedure, No (%)‡ | 28 (40) | 42 (58) | 31 (44) | 38 (53) | 111 (52) | 139 (49) |
Patients receiving NSAIDs at baseline, No (%) | 56 (80) | 55 (76) | 57 (81) | 56 (78) | 168 (79) | 224 (79) |
Corticosteroids, No (%) | 54 (77) | 55 (76) | 9 (70) | 54 (75) | 158 (74) | 212 (75) |
TJC (0–68), n | 30.9 (13.1) | 31.7 (13.2) | 31.0 (12.3) | 32.5 (12.8) | 31.7 (12.7) | 31.5 (12.8) |
SJC (0–66), n | 20.2 (7.4) | 19.6 (9.0) | 18.7 (7.7) | 19.6 (8.3) | 19.3 (8.3) | 19.5 (8.1) |
Patient assessment of pain (scale, 0–100 mm on VAS)§ | 72.4 (18.6) | 73.1 (18.0) | 73.4 (19.4) | 67.9 (23.1) | 71.5 (20.4) | 71.7 (19.9) |
Patient global assessment of disease activity (scale 0–100 mm on VAS)¶ | 73.5 (19.3) | 74.0 (19.9) | 75.7 (19.5) | 69.3 (24.2) | 73.0 (21.4) | 73.1 (20.8) |
Doctor global assessment of disease activity (scale 0–100 mm on VAS)¶ | 65.4 (17.8) | 65.6 (17.6) | 64.8 (18.2) | 63.9 (20.6) | 64.8 (18.8) | 64.9 (18.5) |
Disability index of the HAQ (scale 0 to 3)** | 1.63 (0.67) | 1.79 (0.64) | 1.74 (0.66) | 1.66 (0.73) | 1.73 (0.68) | 1.71 (0.67) |
CRP, mg/l | 63 (44) | 57 (40) | 56 (39) | 60 (55) | 58 (45) | 59 (45) |
ESR, mm/1st h | 53.6 (27.9) | 52.9 (31.0) | 51.7 (27.4) | 50.7 (24.8) | 51.8 (27.7) | 52.2 (27.7) |
DAS28 (scale 2–10)†† | 7.1 (0.8) | 7.0 (1.0) | 7.1 (0.8) | 7.0 (1.0) | 7.0 (0.9) | 7.0 (0.9) |